Arbutus Biopharma Corp Dossier - Source-backed chat

Arbutus Biopharma Corp

ABUSNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)0.74

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $4.78Price as of 30 Sep 2026

Data confidenceNot applicable

Market Cap $946.9M

Enterprise Value $927.8M

Shares Outstanding 197.3M diluted

Moat Rating Wide

Next Earnings Date16 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Arbutus Biopharma is positioned for a transformative phase of growth and capital return, driven by a massive $2.25 billion global patent settlement with Moderna and a highly promising clinical pipeline targeting a functional cure for chronic Hepatitis B (cHBV). The settlement, which includes a noncontingent $950 million upfront payment due in July 2026, provides Arbutus with substantial non-dilutive cash inflows (20% direct entitlement after litigation costs, plus a 16% equity stake in Genevant). This financial windfall completely de-risks the company's balance sheet, supports a planned return of capital to shareholders in Q3 2026, and fully funds the clinical development of its lead RNAi therapeutic, imdusiran (AB-729). Imdusiran has demonstrated a remarkable 50% functional cure rate in select Phase 2a patient cohorts and recently received FDA Fast Track designation, validating its potential to address a massive global unmet medical need.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets1 analysts · as of 18 Aug 2026

Low · most bearish analyst$5.50

Mean target$5.50

High · most bullish analyst$5.50

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

The bear case assumes that the Federal Circuit rules in favor of Moderna on the Section 1498 appeal, permanently blocking the contingent $1.3 billion payment. Furthermore, the planned return of capital in Q3 2026 is smaller than expected due to high legal and operational expenses. On the clinical side, imdusiran's Phase 2b trial experiences enrollment delays or fails to replicate the high functional cure rates observed in Phase 2a, and the Pfizer/BioNTech litigation ends in an unfavorable ruling or a minimal settlement.

Base CaseCentral scenario

The base case assumes the successful receipt of the $950 million upfront Moderna payment in July 2026, with Arbutus executing a meaningful return of capital to shareholders in Q3 2026 while retaining sufficient cash to fund its operations well past 2028. The core clinical thesis is driven by imdusiran advancing into a robust Phase 2b trial, maintaining its strong safety profile and high functional cure rates. Additionally, ongoing litigation against Pfizer/BioNTech continues to progress favorably, providing further long-term valuation optionality.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Transformative $2.25 billion global settlement with Moderna resolves outstanding LNP patent disputes and validates Arbutus's intellectual property estate.
Substantial near-term cash inflow from the $950 million upfront payment due in July 2026, with management actively evaluating a return of capital to shareholders in Q3 2026.
Highly differentiated clinical pipeline led by imdusiran (AB-729), which has achieved a 50% functional cure rate in HBeAg-negative cHBV patients with baseline HBsAg < 1000 IU/mL.
FDA Fast Track designation granted for imdusiran in April 2026, facilitating expedited development and regulatory review.
Significant remaining legal optionality from the ongoing Pfizer/BioNTech litigation, targeting a vaccine market that represents two-thirds of global COVID-19 mRNA sales.

Key Investment Risks

The contingent $1.3 billion portion of the Moderna settlement is highly dependent on a favorable appellate ruling regarding the Section 1498 government-contractor immunity defense.
Clinical development of imdusiran and oral PD-L1 inhibitor AB-101 is subject to inherent trial, regulatory, and commercialization risks.
The company's pre-commercial status means it currently generates no product revenue and remains reliant on partnership milestones and litigation proceeds to sustain long-term operations.

Thesis Invalidation Triggers

An unfavorable appellate ruling on Section 1498 that completely eliminates the contingent $1.3 billion Moderna payment.
Failure of the Board to approve or execute the anticipated return of capital to shareholders in Q3 2026.
Safety concerns or a lack of efficacy in the upcoming imdusiran Phase 2b clinical trial.
An adverse final ruling in the ongoing Pfizer/BioNTech patent infringement litigation.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.